IBS-C Treatment in Kids & Adults: New Drug Studies

Irritable bowel syndrome with constipation (IBS-C) is a disorder of gut-brain interaction characterized by infrequent, hard stools and recurrent abdominal pain. Management often requires addressing multiple physiological mechanisms, from impaired intestinal motility to visceral hypersensitivity. Two recent studies provide new direction for treatment by focusing on specific drug mechanisms in children and addressing pelvic floor dysfunction in adults.

Linaclotide Fills a Gap in Pediatric IBS-C Therapy

For children and adolescents, pharmacologic options for IBS-C have been extremely limited. The FDA’s 2026 approval of linaclotide for patients aged 7 years and older changes this. A review by pediatric gastroenterologists Miguel Linares and Miguel Saps from the University of Miami explains the drug’s dual action. Linaclotide is a guanylate cyclase-C agonist. In the intestinal lining, it triggers a process that increases the secretion of chloride and bicarbonate into the gut. This action draws water into the intestine, softening stools and promoting bowel movements.

More critically, preclinical data indicate linaclotide also reduces the activity of visceral nociceptors—the nerves that signal abdominal pain to the brain. This dual effect on secretion and pain signaling makes it a targeted therapy for the core symptoms of pediatric IBS-C. The approval was supported by a confirmatory regulatory trial and real-world data showing consistent benefit for both bowel and abdominal symptoms.

Pelvic Floor Dysfunction Explains Some “Treatment-Resistant” IBS-C

For many adults, persistent IBS-C symptoms may originate outside the colon. A 2026 multidisciplinary Belgian consensus guideline, authored by Charlotte Van de Bruaene and 27 colleagues, provides a major update on Obstructive Defecation Syndrome (ODS). ODS is a pelvic floor disorder where patients struggle to evacuate stool despite the urge to go, often straining excessively or experiencing a sensation of blockage.

The guideline establishes that ODS is a distinct condition often overlapping with IBS-C. A key finding is that laxatives, which target the colon’s contents, are often insufficient for ODS because the problem is mechanical. The first-line, evidence-based treatment is not more medication, but pelvic floor physical therapy. This therapy uses biofeedback to retrain the dysfunctional coordination of abdominal and pelvic floor muscles during defecation. The consensus stresses that accurate diagnosis, which may involve anorectal manometry, is required to identify patients who will benefit from this targeted approach.

Practical Applications for a Multi-System Disorder

These studies show that modern IBS-C management is driven by subtype. The first step is a thorough clinical assessment to identify the likely dominant problem: slow-transit constipation, visceral hypersensitivity, or pelvic floor dysfunction (ODS). For patients with predominant pain and constipation—particularly children and adolescents—linaclotide represents a new option with a specific intestinal mechanism.

For adults with symptoms of straining and incomplete evacuation, the pelvic floor must be evaluated. As detailed in our article on ODS, referral to a specialist for assessment and potential biofeedback therapy can be transformative when standard treatments fail. Dietary management, including soluble fiber like psyllium and a low-FODMAP protocol supervised by a dietitian, remains a cornerstone for managing gut symptoms and modulating the gut-brain axis.

Frequently Asked Questions

My child has IBS-C. Is linaclotide safe for them?

The U.S. FDA approved linaclotide in 2026 for children aged 7 and older with IBS-C based on clinical trial data. The most common side effect is diarrhea, which underscores the importance of using it under a pediatric gastroenterologist’s supervision to manage dosing.

I’ve tried many laxatives for my IBS-C with little success. What else could it be?

You may have Obstructive Defecation Syndrome (ODS), a pelvic floor coordination problem. Laxatives soften stool but don’t fix the muscular dysfunction of evacuation. An evaluation for ODS, which may lead to pelvic floor physical therapy, is a recommended next step.

Is IBS-C treatment now just about taking a pill?

No. Even with new medications like linaclotide, experts like Linares and Saps emphasize its role within “multidisciplinary care pathways.” Optimal management combines targeted pharmacology with dietary strategies, stress reduction, and, when indicated, physical therapy for the pelvic floor.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42425925/
https://pubmed.ncbi.nlm.nih.gov/42417642/